Monitor upcoming shareholder vote on stock issuance for commitment fee and watch for any changes in cash flow or development timelines that could trigger covenant compliance issues. The royalty agreement creates long-term value-sharing with a major shareholder that could influence future partnership decisions.
Price Chart
Executive Summary
TuHURA Biosciences secured a $50 million revolving credit facility from Parkview Holdings, an affiliate of its largest shareholder, secured by company assets with a 12% interest rate. In exchange, the company granted royalty rights on future IFx-2.0 product sales and agreed to extend the maturity of existing warrants held by the same investor group. This transaction provides capital through 2028 while creating significant financial obligations and potential conflicts of interest.
Key Financial Metrics
Key Facts
- Entered into $50 million revolving credit facility with Parkview Holdings One LLC, an affiliate of largest shareholder K&V Investment One LLC
- Loan bears 12% annual interest, secured by substantially all company assets, maturing April 21, 2031
- Agreed to pay $5 million commitment fee via issuance of 1,878,287 shares of common stock (subject to shareholder approval)
- Granted royalty of low-to-mid single digits on annual sales of IFx-2.0 products up to $450 million, continuing through patent expiration
- Extended exercise period of 4,364,873 warrants held by K&V Investment One LLC from 2027/2029 to 2031
- Lender gains right to appoint board director and conversion rights in case of change of control
Financial Impact
Up to $50 million debt facility with 12% interest, $5 million commitment fee paid in stock, and contingent royalty payments on future product sales
Risk Factors
- High 12% interest rate increases financial burden
- Potential conflict of interest with lender being affiliate of largest shareholder
- Default risk if company discontinues IFx-2.0 development program or experiences change of control
- Shareholder dilution from issuance of 1.88 million shares for commitment fee
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-168395 |
| Document: d139552dex101.htm | 0001193125-26-168395 |
| Document: d139552d8k.htm | 0001193125-26-168395 |
| Document: d139552dex104.htm | 0001193125-26-168395 |
| Document: d139552dex103.htm | 0001193125-26-168395 |
| Document: d139552dex991.htm | 0001193125-26-168395 |
| Document: d139552dex102.htm | 0001193125-26-168395 |
| Document: 0001193125-26-168395-index-headers.html | 0001193125-26-168395 |
| Document: 0001193125-26-168395-index.html | 0001193125-26-168395 |
| Document: 0001193125-26-168395.txt | 0001193125-26-168395 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.78 | awaiting T+60 | — | $2.07 (+16.22%) |
Sep 24, 2026 4w ago | 8-K | $2.10 | awaiting T+60 | — | $2.07 (−1.49%) |
Sep 17, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $2.07 (−1.49%) |
Sep 16, 2026 5w ago | 8-K | $2.09 | awaiting T+60 | — | $2.07 (−1.01%) |
Sep 4, 2026 7w ago | 8-K | $2.12 | awaiting T+60 | — | $2.07 (−2.42%) |
Aug 19, 2026 9w ago | 8-K | $2.22 | awaiting T+60 | — | $2.07 (−6.81%) |
Aug 14, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.07 (−16.24%) |
Aug 14, 2026 10w ago | Press Release | $2.47 | awaiting T+60 | — | $2.07 (−16.24%) |
Aug 13, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.07 (−16.24%) |
Jul 29, 2026 12w ago | 8-K | $2.17 $2.18 | ▲ +0.46% | ▼ −2.00% | $2.07 (−4.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers